- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 77.07%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | -0.11 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (9) | 0.41 | -30.51 | 0.18 | -62.5 | 0.00 | 0 | 43.90 | -46.04 | 0.00 | 0 | 43.90 | -46.04 |
| 2021 (8) | 0.59 | -58.74 | 0.48 | -56.36 | 0.00 | 0 | 81.36 | 5.76 | 0.00 | 0 | 81.36 | 5.76 |
| 2020 (7) | 1.43 | -3.38 | 1.10 | -17.91 | 0.00 | 0 | 76.92 | -15.04 | 0.00 | 0 | 76.92 | -15.04 |
| 2019 (6) | 1.48 | 8.82 | 1.34 | 6.35 | 0.00 | 0 | 90.54 | -2.27 | 0.00 | 0 | 90.54 | -2.27 |
| 2018 (5) | 1.36 | 10.57 | 1.26 | 306.45 | 0.00 | 0 | 92.65 | 267.6 | 0.00 | 0 | 92.65 | 2.66 |
| 2017 (4) | 1.23 | 459.09 | 0.31 | 0 | 0.80 | 0 | 25.20 | 0 | 65.04 | 0 | 90.24 | 0 |
| 2016 (3) | 0.22 | -86.08 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 0.33 | 1750.0 | 925.0 | 0.30 | 850.0 | 850.0 | 0.06 | 122.22 | 0 |
| 24Q2 (19) | -0.02 | 91.67 | -108.0 | -0.04 | 81.82 | -123.53 | -0.27 | -12.5 | -775.0 |
| 24Q1 (18) | -0.24 | -100.0 | -14.29 | -0.22 | -144.44 | 0.0 | -0.24 | -118.18 | -14.29 |
| 23Q4 (17) | -0.12 | -200.0 | -9.09 | -0.09 | -125.0 | 30.77 | -0.11 | 0 | -126.83 |
| 23Q3 (16) | -0.04 | -116.0 | -120.0 | -0.04 | -123.53 | -118.18 | 0.00 | -100.0 | -100.0 |
| 23Q2 (15) | 0.25 | 219.05 | -53.7 | 0.17 | 177.27 | -73.85 | 0.04 | 119.05 | -87.5 |
| 23Q1 (14) | -0.21 | -90.91 | 4.55 | -0.22 | -69.23 | -29.41 | -0.21 | -151.22 | 4.55 |
| 22Q4 (13) | -0.11 | -155.0 | -118.64 | -0.13 | -159.09 | -130.23 | 0.41 | -21.15 | -30.51 |
| 22Q3 (12) | 0.20 | -62.96 | 0 | 0.22 | -66.15 | 450.0 | 0.52 | 62.5 | 5100.0 |
| 22Q2 (11) | 0.54 | 345.45 | 116.0 | 0.65 | 482.35 | 116.67 | 0.32 | 245.45 | 3100.0 |
| 22Q1 (10) | -0.22 | -137.29 | 12.0 | -0.17 | -139.53 | 22.73 | -0.22 | -137.29 | 12.0 |
| 21Q4 (9) | 0.59 | 0 | 31.11 | 0.43 | 975.0 | 43.33 | 0.59 | 5800.0 | -59.03 |
| 21Q3 (8) | 0.00 | -100.0 | -100.0 | 0.04 | -86.67 | -89.74 | 0.01 | 0.0 | -98.99 |
| 21Q2 (7) | 0.25 | 200.0 | -53.7 | 0.30 | 236.36 | -42.31 | 0.01 | 104.0 | -98.15 |
| 21Q1 (6) | -0.25 | -155.56 | -377.78 | -0.22 | -173.33 | -269.23 | -0.25 | -117.36 | -377.78 |
| 20Q4 (5) | 0.45 | 0.0 | -26.23 | 0.30 | -23.08 | -42.31 | 1.44 | 45.45 | -3.36 |
| 20Q3 (4) | 0.45 | -16.67 | 0.0 | 0.39 | -25.0 | 0.0 | 0.99 | 83.33 | 0.0 |
| 20Q2 (3) | 0.54 | 500.0 | 0.0 | 0.52 | 300.0 | 0.0 | 0.54 | 500.0 | 0.0 |
| 20Q1 (2) | 0.09 | -85.25 | 0.0 | 0.13 | -75.0 | 0.0 | 0.09 | -93.96 | 0.0 |
| 19Q4 (1) | 0.61 | 0.0 | 0.0 | 0.52 | 0.0 | 0.0 | 1.49 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 0.25 | 8.0 | 14.95 | 2.6 | 13.66 | 0.72 | N/A | - | ||
| 2024/9 | 0.23 | -4.7 | -24.67 | 2.35 | 13.53 | 0.9 | 0.48 | - | ||
| 2024/8 | 0.24 | -44.02 | -14.3 | 2.12 | 20.16 | 0.91 | 0.47 | - | ||
| 2024/7 | 0.43 | 86.8 | 100.15 | 1.88 | 26.74 | 1.0 | 0.43 | 各產品項目皆成長，主係因儀器銷售增加 | ||
| 2024/6 | 0.23 | -30.48 | -12.58 | 1.44 | 14.13 | 0.76 | 0.8 | - | ||
| 2024/5 | 0.33 | 69.93 | 32.69 | 1.21 | 21.19 | 0.75 | 0.81 | - | ||
| 2024/4 | 0.2 | -11.86 | -24.27 | 0.88 | 17.34 | 0.62 | 0.98 | - | ||
| 2024/3 | 0.22 | 10.1 | 8.19 | 0.68 | 39.25 | 0.68 | 0.67 | - | ||
| 2024/2 | 0.2 | -22.4 | 29.2 | 0.46 | 61.56 | 0.73 | 0.63 | 各產品項目皆成長，主係因測試收入增加 | ||
| 2024/1 | 0.26 | -2.88 | 100.54 | 0.26 | 100.54 | 0.78 | 0.59 | 各產品項目皆成長，主係因儀器銷售增加 | ||
| 2023/12 | 0.27 | 6.23 | 6.91 | 2.81 | -12.84 | 0.74 | 0.73 | - | ||
| 2023/11 | 0.25 | 16.4 | 9.23 | 2.54 | -14.51 | 0.77 | 0.7 | - | ||
| 2023/10 | 0.22 | -29.23 | -10.31 | 2.29 | -16.51 | 0.8 | 0.67 | - | ||
| 2023/9 | 0.31 | 8.41 | 11.48 | 2.07 | -17.11 | 0.8 | 0.56 | - | ||
| 2023/8 | 0.28 | 30.72 | 30.29 | 1.76 | -20.65 | 0.76 | 0.59 | - | ||
| 2023/7 | 0.22 | -18.41 | -6.45 | 1.48 | -26.15 | 0.73 | 0.62 | - | ||
| 2023/6 | 0.26 | 5.52 | -34.57 | 1.27 | -28.67 | 0.77 | 0.72 | - | ||
| 2023/5 | 0.25 | -3.01 | 9.19 | 1.0 | -26.93 | 0.71 | 0.78 | - | ||
| 2023/4 | 0.26 | 25.92 | -38.47 | 0.75 | -34.21 | 0.62 | 0.9 | - | ||
| 2023/3 | 0.21 | 31.47 | -37.95 | 0.49 | -31.71 | 0.49 | 0.69 | - | ||
| 2023/2 | 0.16 | 20.43 | 18.63 | 0.29 | -26.4 | 0.54 | 0.63 | - | ||
| 2023/1 | 0.13 | -48.22 | -49.49 | 0.13 | -49.49 | 0.61 | 0.56 | - | ||
| 2022/12 | 0.25 | 8.53 | -39.4 | 3.22 | 2.95 | 0.72 | 0.47 | - | ||
| 2022/11 | 0.23 | -4.42 | -38.79 | 2.97 | 9.41 | 0.75 | 0.46 | - | ||
| 2022/10 | 0.24 | -12.02 | -11.04 | 2.74 | 17.19 | 0.73 | 0.46 | - | ||
| 2022/9 | 0.27 | 26.7 | -6.11 | 2.5 | 20.91 | 0.72 | 0.35 | - | ||
| 2022/8 | 0.22 | -6.14 | 15.49 | 2.22 | 25.36 | 0.85 | 0.29 | - | ||
| 2022/7 | 0.23 | -42.93 | -33.33 | 2.0 | 26.53 | 0.87 | 0.29 | - | ||
| 2022/6 | 0.4 | 76.12 | 35.6 | 1.77 | 43.28 | 1.05 | 0.34 | - | ||
| 2022/5 | 0.23 | -45.36 | 17.98 | 1.37 | 45.71 | 0.98 | 0.37 | - | ||
| 2022/4 | 0.42 | 26.98 | 60.37 | 1.14 | 52.96 | 0.88 | 0.41 | 由於客戶需求增加,致各產品項目皆有所成長,以測試收入成長最多 | ||
| 2022/3 | 0.33 | 151.39 | 81.44 | 0.72 | 48.94 | 0.72 | 0.79 | 各產品項目皆有成長,主係因儀器及檢測收入增加所致 | ||
| 2022/2 | 0.13 | -48.72 | -28.93 | 0.39 | 29.22 | 0.8 | 0.71 | - | ||
| 2022/1 | 0.26 | -37.87 | 122.67 | 0.26 | 122.67 | 1.05 | 0.54 | 各產品項目皆有成長,主係因檢測收入增加所致 | ||
| 2021/12 | 0.41 | 9.62 | 14.62 | 3.13 | -21.46 | 1.06 | 0.25 | - | ||
| 2021/11 | 0.38 | 38.9 | 2.97 | 2.71 | -25.05 | 0.94 | 0.29 | - | ||
| 2021/10 | 0.27 | -7.14 | -17.9 | 2.34 | -28.21 | 0.75 | 0.36 | - | ||
| 2021/9 | 0.29 | 55.86 | 8.27 | 2.06 | -29.38 | 0.83 | 0.57 | - | ||
| 2021/8 | 0.19 | -45.82 | -45.75 | 1.77 | -33.21 | 0.83 | 0.56 | - | ||
| 2021/7 | 0.35 | 16.07 | -7.38 | 1.58 | -31.33 | 0.84 | 0.56 | - | ||
| 2021/6 | 0.3 | 53.23 | 6.58 | 1.24 | -35.96 | 0.76 | 0.64 | - | ||
| 2021/5 | 0.19 | -25.73 | -54.16 | 0.94 | -43.16 | 0.64 | 0.75 | 因去年同期儀器設備及試劑耗材銷售額增加,導致本月較去年同期營收減少 | ||
| 2021/4 | 0.26 | 43.67 | -15.64 | 0.75 | -39.36 | 0.63 | 0.76 | - | ||
| 2021/3 | 0.18 | -1.53 | -58.18 | 0.48 | -47.38 | 0.48 | 0.81 | 因去年同期基因檢測收入增加,導致本月較去年同期營收減少 | ||
| 2021/2 | 0.19 | 60.65 | -31.05 | 0.3 | -37.61 | 0.66 | 0.59 | - | ||
| 2021/1 | 0.12 | -68.01 | -45.88 | 0.12 | -45.88 | 0.84 | 0.46 | - | ||
| 2020/12 | 0.36 | -1.51 | -21.6 | 3.98 | -4.64 | 1.06 | 0.17 | - | ||
| 2020/11 | 0.37 | 10.73 | -19.64 | 3.62 | -2.54 | 0.97 | 0.19 | - | ||
| 2020/10 | 0.33 | 22.47 | -15.91 | 3.25 | -0.15 | 0.95 | 0.19 | - | ||
| 2020/9 | 0.27 | -21.91 | -34.36 | 2.92 | 2.01 | 0.99 | 0.3 | - | ||
| 2020/8 | 0.35 | -7.5 | -30.14 | 2.65 | 8.11 | 1.0 | 0.3 | - | ||
| 2020/7 | 0.37 | 33.59 | 3.97 | 2.31 | 17.77 | 1.08 | 0.28 | - | ||
| 2020/6 | 0.28 | -34.1 | -24.1 | 1.93 | 20.88 | 1.02 | 0.43 | - | ||
| 2020/5 | 0.42 | 36.69 | 26.52 | 1.65 | 34.36 | 1.17 | 0.38 | - | ||
| 2020/4 | 0.31 | -28.79 | 22.65 | 1.23 | 37.3 | 1.02 | 0.43 | - | ||
| 2020/3 | 0.44 | 62.35 | 55.1 | 0.92 | 43.08 | 0.92 | 0.54 | 客戶需求增加 | ||
| 2020/2 | 0.27 | 26.11 | 35.94 | 0.48 | 33.69 | 0.94 | 0.53 | - | ||
| 2020/1 | 0.21 | -53.67 | 30.95 | 0.21 | 30.95 | 1.13 | 0.44 | - | ||
| 2019/12 | 0.46 | 0.94 | 0.01 | 4.17 | 8.59 | 0.0 | N/A | - | ||
| 2019/11 | 0.46 | 15.87 | 22.9 | 3.71 | 9.76 | 0.0 | N/A | - |
